Diabetes
The global burden of metabolic disease: data from 2000 to 2019
13 Mar, 2023 | 14:39h | UTCThe global burden of metabolic disease: Data from 2000 to 2019 – Cell Metabolism (free for a limited period)
Current recommendations for management of pediatric diabetic ketoacidosis
10 Mar, 2023 | 14:38h | UTC
Maternal diabetes and overweight as risk factors for congenital heart defects in offspring – A nationwide register study from Finland
3 Mar, 2023 | 13:51h | UTCSummary: The study aimed to determine the association between maternal diabetes and overweight/obesity and the risk of congenital heart defects (CHDs) in offspring. The study analyzed data from all children born in Finland between 2006 and 2016 and their mothers. Maternal type 1 diabetes (T1DM) was found to be associated with a significantly increased risk for any CHD, with an odds ratio of 3.71, whereas maternal overweight and obesity were associated with only a slightly increased risk for complex defects and left ventricular outflow tract obstruction. Maternal diabetes was responsible for 3.0% of offspring’s CHD, while maternal overweight and obesity were responsible for 0.7%, indicating weaker associations between maternal overweight and obesity and CHD in the offspring than previously reported.
Commentary from the author on Twitter
Proudly presenting our preprint (thread):
Maternal diabetes and overweight as risk factors for congenital heart defects in offspring – A nationwide register study from Finland https://t.co/rFnlNYPrgn 1/7
— Emmi Helle (@EmmiHelle) February 27, 2023
Youth-onset type 2 diabetes: the epidemiology of an awakening epidemic
2 Mar, 2023 | 13:01h | UTCYouth-Onset Type 2 Diabetes: The Epidemiology of an Awakening Epidemic – Diabetes Care
RCT | Empagliflozin (SGLT2i) is more effective for reducing HbA1c than linagliptin (DPP-4i) in young people with Type 2 DM
2 Mar, 2023 | 13:00h | UTCEfficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Commentaries:
DINAMO: Empagliflozin shows promise for young people with type 2 diabetes – medwire News
M-A | Combination of multiple low-risk lifestyle behaviors and incident type 2 diabetes
1 Mar, 2023 | 14:06h | UTCSummary: This systematic review and meta-analysis assessed the association between multiple low-risk lifestyle behaviors (LRLBs) and the incidence of type 2 diabetes. The study examined 30 cohort comparisons involving 1,693,753 participants and 75,669 cases of type 2 diabetes. The LRLBs evaluated in the study were maintaining a healthy body weight, healthy diet, regular exercise, smoking abstinence or cessation, and light alcohol consumption. Results showed that the highest adherence to these LRLBs was associated with an 80% lower risk of type 2 diabetes compared to the lowest adherence group. Thus, targeting these LRLBs could be an effective strategy for the primary prevention of type 2 diabetes. However, the authors recommend promoting only four LRLBs, excluding alcohol intake, due to its association with increased harm. The potential benefits of small alcohol intake remain a controversial issue since most studies on the subject are observational and subject to residual confounding.
Article: Combination of Multiple Low-Risk Lifestyle Behaviors and Incident Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies – Diabetes Care (free for a limited period)
Commentary from the author on Twitter (thread – click for more)
Our research shows that adherence to multiple low-risk lifestyle behaviours including healthy diet and exercise can significantly reduce the risk of type 2 diabetes https://t.co/mWEEw9xYtQ #healthylifestyle #lowriskhabits #healthresearch
— Tauseef Khan (@tauseefkhan) February 22, 2023
RCT | Physician-led medication reviews in polypharmacy patients with Type 2 DM treated with at least 12 medications
1 Mar, 2023 | 13:36h | UTC
Review | Embracing complexity: making sense of diet, nutrition, obesity and type 2 diabetes
28 Feb, 2023 | 13:42h | UTCEmbracing complexity: making sense of diet, nutrition, obesity and type 2 diabetes – Diabetologia
Commentary on Twitter
Comprehensive Review @DiabetologiaJnl by my very talented friend Prof Nita Forouhi
Embracing complexity: making sense of diet, nutrition, obesity & T2 diabeteshttps://t.co/PxGOZL0XkB pic.twitter.com/x2GaDPClfi
— Prof Kamlesh Khunti (@kamleshkhunti) February 24, 2023
Under a http://creativecommons.org/licenses/by/4.0/ license
RCT | Tight glycemic control did not preserve pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes
27 Feb, 2023 | 13:16h | UTCSummary: The study aimed to determine if intensive diabetes management with an automated insulin delivery system could help preserve pancreatic beta cell function in youth with newly diagnosed type 1 diabetes. The randomized clinical trial included 113 youths aged 7 to 17 years and found that although the mean time in the target range of 70 to 180 mg/dL was 78% in the intensive management group vs. 64% in the standard care group, intensive diabetes management did not affect the decline in pancreatic C-peptide secretion at 52 weeks. The study concluded that near normalization of glucose levels instituted immediately after diagnosis of type 1 diabetes did not preserve pancreatic beta cell function in youth.
Article: Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Preserving Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes – JAMA (free for a limited period)
Commentary on Twitter
Intensive diabetes management with automated insulin delivery did not affect the decline in pancreatic C-peptide secretion at 52 weeks in youths with newly diagnosed type 1 diabetes. https://t.co/e1n5xagrtv #ATTD2023 pic.twitter.com/C6743BmqyH
— JAMA (@JAMA_current) February 24, 2023
RCT | Verapamil partially preserved pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes
27 Feb, 2023 | 13:14h | UTCSummary: The study aimed to determine whether verapamil could preserve pancreatic beta cell function in children and adolescents with newly diagnosed type 1 diabetes. The randomized clinical trial involved 88 participants who were given either verapamil or placebo once daily for 52 weeks. The study found that C-peptide levels were 30% higher in the verapamil group compared to the placebo group at 52 weeks, and the percentage of participants with a 52-week peak C-peptide level of 0.2 pmol/mL or greater was 95% in the verapamil group compared to 71% in the placebo group. The study also found that verapamil was well tolerated with few adverse events. The results suggest that verapamil may partially preserve stimulated C-peptide secretion in children and adolescents with newly diagnosed type 1 diabetes. However, further studies with patient-relevant outcomes are needed to determine the long-term effectiveness and the optimal length of therapy.
Article: Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Preserving Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes – JAMA (free for a limited period)
News Release: Verapamil shows beneficial effect on the pancreas in children with newly-diagnosed type 1 diabetes – University of Minnesota
Commentary on Twitter
In youth with newly diagnosed type 1 diabetes, verapamil partially preserved stimulated C-peptide secretion at 52 weeks from diagnosis compared with placebo. https://t.co/m4xbczf93C #ATTD2023 pic.twitter.com/teM0jjh1tT
— JAMA (@JAMA_current) February 24, 2023
Cohort Study | Association of large-for-gestational age birth and prediabetes/diabetes 10-14 years’ postpartum
24 Feb, 2023 | 13:43h | UTCSummary: Several studies show that women who develop diabetes during pregnancy are at increased risk of developing diabetes later in life. This study investigated whether giving birth to a larger-than-normal baby is associated with an increased risk of prediabetes or diabetes 10-14 years after pregnancy in individuals without gestational diabetes. The study used data from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Follow-up Study, including pregnant individuals without gestational diabetes. After adjusting for various baseline maternal characteristics, the researchers found that individuals who gave birth to a large-for-gestational age (LGA) infant had a 21% higher risk of being diagnosed with prediabetes or diabetes 10-14 years after delivery compared to those who had an appropriate-for-gestational age (AGA) infant. The study concluded that having a previous LGA infant is a marker of increased risk of developing prediabetes or diabetes in individuals without gestational diabetes.
Abstract: Association of large-for-gestational age birth and prediabetes/diabetes 10-14 years’ postpartum in the HAPO follow-up study – American Journal of Obstetrics & Gynecology (link to abstract, presented at the Society for Maternal-Fetal Medicine’s annual meeting)
Commentaries:
Delivering a Plus-Sized Baby Could Be Sign of Diabetes Risk – HealthDay
Large for Gestational Age Births Could Increase Diabetes Risk in Women – HCP Live
M-A | Low-dose insulin infusion is safe and effective in treating diabetic ketoacidosis in children
23 Feb, 2023 | 13:40h | UTCSummary: The article discusses a systematic review and meta-analysis of randomized controlled trials comparing low-dose insulin at 0.05 units/kg/hr to standard dose at 0.1 units/kg/hr for children with diabetic ketoacidosis (DKA). The study found that low-dose insulin infusion is probably as efficacious and safer than standard-dose insulin in treating DKA in children, as it has no effect on the time to resolution of hyperglycemia or acidosis and probably reduces the risk of developing hypokalemia and hypoglycemia. However, the results are limited by imprecision and generalizability to other settings since all studies were performed in a single country. Therefore, further studies are required to identify the optimal insulin dose for children with DKA in terms of safety and effectiveness.
Review | Diagnosis and management of patients with polyneuropathy
21 Feb, 2023 | 11:40h | UTCDiagnosis and management of patients with polyneuropathy – Canadian Medical Association Journal
Consensus Statement | Evaluation and management of patients with diabetes and heart failure
10 Feb, 2023 | 13:51h | UTCRelated:
ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison – ESC Heart Failure
#ACC22 – 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
M-A | Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus
10 Feb, 2023 | 13:38h | UTC
Cohort Study | The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults
9 Feb, 2023 | 13:28h | UTC
RCT | Outcomes in children of women with type 2 diabetes exposed to metformin vs. placebo during pregnancy
8 Feb, 2023 | 12:32h | UTCOutcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Crossover RCT | Effects of SGLT2 inhibition on sodium in patients with chronic syndrome of inappropriate antidiuresis
8 Feb, 2023 | 12:34h | UTC
Commentary on Twitter
The syndrome of inappropriate antidiuresis (SIAD) is a major cause of hypotonic hyponatremia. This study shows the SGLT2 inhibitor empagliflozin is a promising new treatment for chronic SIAD-induced hyponatremia, possibly improving neurocognitive function https://t.co/U26RNmVM9j pic.twitter.com/8pH6xqSs7D
— JASN_News (@JASN_News) December 12, 2022
Crossover RCT | Effects of liquid glucagon on preventing exercise-associated hypoglycemia in adults with Type 1 DM
6 Feb, 2023 | 13:08h | UTCEffect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes – Diabetes Care (free for a limited period)
RCT | Efficacy and safety of intermittent fasting in people with insulin-treated Type 2 Diabetes
3 Feb, 2023 | 13:54h | UTCCommentary: Intermittent fasting feasible with insulin-treated type 2 diabetes – medwire News
Related:
RCT | Effect of an intermittent calorie-restricted diet on Type 2 DM remission.
Intermittent fasting may be effective weight loss strategy in patients with type 2 diabetes
Clinical Management of Intermittent Fasting in Patients with Diabetes Mellitus
Cardiometabolic multimorbidity and incident dementia: the Swedish twin registry
3 Feb, 2023 | 13:45h | UTCEditorial: Deciphering dementia in the cardiometabolic continuum – European Heart Journal
Position Paper | Exercise recommendations for people with type 1 and type 2 diabetes
2 Feb, 2023 | 14:55h | UTC
Guidelines for the management of hypertension in patients with diabetes mellitus
1 Feb, 2023 | 13:17h | UTC
M-A | Association between autism spectrum disorders and cardiometabolic diseases
1 Feb, 2023 | 13:11h | UTCAssociation Between Autism Spectrum Disorders and Cardiometabolic Diseases: A Systematic Review and Meta-analysis – JAMA Pediatrics (free for a limited period)
Editorial: Autism, Physical Health Conditions, and a Need for Reform – JAMA Pediatrics (free for a limited period)
Commentary on Twitter
Study results suggest that having autism may be associated with a higher risk of developing diabetes, dyslipidemia, and heart disease. https://t.co/T19VAQxdjf
— JAMA Pediatrics (@JAMAPediatrics) January 30, 2023
M-A | Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and CKD
1 Feb, 2023 | 13:06h | UTC